Trintellix vs Vraylar
Side-by-side cost comparison based on Medicare Part D data
Trintellix
Vortioxetine
Manufactured by Takeda
Vraylar
Cariprazine
Manufactured by AbbVie
Trintellix costs 27% less per claim than Vraylar ($278.00 vs $383.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Trintellix | Vraylar |
|---|---|---|
| Avg Cost Per Claim | $278.00 | $383.00 |
| Total Medicare Spending | $1.1B | $1.7B |
| Total Beneficiaries | 425,000 | 486,000 |
| Total Claims | 3,840,000 | 4,320,000 |
| Annual Cost/Patient | $2,511.00 | $3,403.00 |
| Year-over-Year Change | +7.8% | +26.3% |
| Generic Available | No | No |
| Patent Expiration | Sep 30, 2026 | Sep 17, 2029 |
| Manufacturer | Takeda | AbbVie |
| Condition | Mental Health | Mental Health |
| Generic Name | Vortioxetine | Cariprazine |
Trintellix vs Vraylar: What the Data Shows
Trintellix (Vortioxetine) and Vraylar (Cariprazine) are both used to treat mental health. Based on Medicare Part D data, Trintellix costs $278.00 per claim, which is 27% less than Vraylar at $383.00 per claim.
Medicare spent $1.1B on Trintellix and $1.7B on Vraylar. In terms of patient reach, Vraylar serves more beneficiaries (486,000 vs 425,000).
Year-over-year spending changed +7.8% for Trintellix and +26.3% for Vraylar. Vraylar saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Trintellix patent expires Sep 30, 2026. Vraylar patent expires Sep 17, 2029.
Frequently Asked Questions
Trintellix is cheaper at $278.00 per claim, compared to $383.00 for Vraylar. That makes Trintellix about 27% less expensive per claim based on Medicare Part D data.
Yes, both Trintellix and Vraylar are used to treat mental health. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Trintellix patent expires Sep 30, 2026. Vraylar patent expires Sep 17, 2029.
Medicare Part D spent $1.1B on Trintellix covering 425,000 beneficiaries, and $1.7B on Vraylar covering 486,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.